Swiss National Bank lifted its position in shares of Repligen Co. (NASDAQ:RGEN) by 8.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 73,500 shares of the biotechnology company’s stock after buying an additional 5,600 shares during the quarter. Swiss National Bank owned approximately 0.16% of Repligen worth $6,317,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Royce & Associates LP boosted its position in shares of Repligen by 40.6% in the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 145 shares during the period. Private Capital Group LLC increased its position in shares of Repligen by 675.3% during the 1st quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 628 shares during the last quarter. South Dakota Investment Council acquired a new position in shares of Repligen during the 1st quarter worth approximately $83,000. Ropes Wealth Advisors LLC acquired a new position in shares of Repligen during the 2nd quarter worth approximately $116,000. Finally, Oppenheimer Asset Management Inc. boosted its stake in Repligen by 14.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 2,385 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 292 shares during the period. Hedge funds and other institutional investors own 81.06% of the company’s stock.
In other Repligen news, Director Karen A. Dawes sold 1,295 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $77.35, for a total value of $100,168.25. Following the sale, the director now owns 118,329 shares in the company, valued at approximately $9,152,748.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.70% of the stock is currently owned by company insiders.
Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.06. The firm had revenue of $70.70 million during the quarter, compared to the consensus estimate of $65.47 million. Repligen had a net margin of 11.42% and a return on equity of 6.92%. Repligen’s revenue was up 48.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 earnings per share. As a group, sell-side analysts forecast that Repligen Co. will post 0.97 earnings per share for the current year.
RGEN has been the subject of several recent research reports. First Analysis increased their price target on Repligen from $95.00 to $107.00 and gave the company an “outperform” rating in a research note on Wednesday. BidaskClub upgraded Repligen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 27th. Zacks Investment Research lowered Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $110.00 target price on shares of Repligen in a research note on Monday, August 12th. Finally, Craig Hallum upped their target price on Repligen from $80.00 to $108.00 and gave the stock a “buy” rating in a report on Monday, August 5th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $101.17.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Read More: How to trade on quiet period expirations
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.